<DOC>
	<DOCNO>NCT00096083</DOCNO>
	<brief_summary>RATIONALE : Hepatic arterial infusion use catheter deliver anticancer substance directly liver . Drugs use chemotherapy , melphalan , work different way stop tumor cell divide stop grow die . Giving drug different way may kill tumor cell . PURPOSE : This phase II trial study well give hepatic arterial infusion melphalan together hepatic perfusion work treat patient unresectable liver cancer .</brief_summary>
	<brief_title>Hepatic Arterial Infusion Melphalan With Hepatic Perfusion Treating Patients With Unresectable Liver Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate duration response patient unresectable primary metastatic liver cancer treat intrahepatic arterial infusion melphalan venous filtration via peripheral hepatic perfusion . Secondary - Determine pattern recurrence patient treat regimen . - Determine progression-free overall survival patient treat regimen . - Evaluate safety tolerability regimen patient . - Assess filter characteristic include melphalan pharmacokinetics filtration cytokine clot factor treatment . OUTLINE : Patients stratify accord primary tumor histology ( neuroendocrine tumor v primary hepatic malignancy v adenocarcinoma gastrointestinal origin ) . Patients undergo peripheral isolate hepatic perfusion catheter place via groin hepatic artery another hepatic vein . Patients receive melphalan intrahepatic arterial infusion 15-30 minute . Treatment repeat approximately every 3-8 week 6 total infusion absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year , every 4 month 1 year , periodically thereafter . PROJECTED ACCRUAL : A total 105 patient accrue study within 4-5 year .</detailed_description>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm hepatic malignancy Unresectable disease Disease predominantly parenchyma liver One follow primary tumor histology : Adenocarcinoma gastrointestinal origin Neuroendocrine tumor ( except gastrinoma ) Primary hepatic malignancy ( e.g. , hepatocellular cancer intrahepatic cholangiocarcinoma ) Cutaneous ocular melanoma ( patient must receive prior regional melphalan therapy ) Hepatic metastasis colorectal tumor allow provided patient undergone prior firstline chemotherapy , include irinotecan oxaliplatin Limited unresectable extrahepatic disease preoperative radiological study allow lifelimiting component progressive disease liver Limited extrahepatic disease include , limited , follow : Up 4 pulmonary nodule &lt; 1 cm diameter Retroperitoneal lymph node &lt; 3 cm diameter Less 10 skin subcutaneous metastasis &lt; 1 cm diameter Asymptomatic bone metastasis could palliatively treat external beam radiotherapy Resectable solitary metastasis site Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 16 Sex Male Female Menopausal status Not specify Performance status ECOG 02 Life expectancy Not specify Hematopoietic Platelet count ≥ 75,000/mm^3 Hematocrit &gt; 27 % Absolute neutrophil count ≥ 1,300/mm^3 Hepatic Bilirubin ≤ 2.0 mg/dL PT ≤ 2 second upper limit normal ( ULN ) AST ALT ≤ 10 time ULN No Childs class B C cirrhosis No portal hypertension history , endoscopy , radiologic study Renal Creatinine ≤ 1.5 mg/dL OR Creatinine clearance &gt; 60 mL/min Cardiovascular No congestive heart failure LVEF ≥ 40 % Pulmonary No chronic obstructive pulmonary disease FEV_1 ≥ 30 % predict DLCO ≥ 40 % predict Immunologic No active infection No severe allergic reaction iodine contrast agent control premedication antihistamine steroids No known hypersensitivity reaction melphalan heparin presence heparin induce thrombocytopenia ( HIT ) antibody Other Weight &gt; 35 kg Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No document latex allergy No evidence intracranial abnormality would lead risk bleed anticoagulation ( e.g. , stroke active metastasis ) No evidence active ulcer disease PRIOR CONCURRENT THERAPY : Biologic therapy More 1 month since prior biologic therapy recover Chemotherapy See Disease Characteristics More 1 month since prior chemotherapy recover Endocrine therapy Premenopausal woman ( i.e. , period within past 12 month ) must willing undergo hormonal suppression study treatment Radiotherapy See Disease Characteristics More 1 month since prior radiotherapy recover Surgery No prior Whipple resection Other Prior intrahepatic perfusion ( without arterial infusion floxuridine ) peripheral hepatic perfusion allow provided patient radiographic partial response 3 month ' duration therapy No concurrent immunosuppressive drug No concurrent chronic anticoagulation therapy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>adenocarcinoma extrahepatic bile duct</keyword>
	<keyword>adenocarcinoma gallbladder</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>carcinoma appendix</keyword>
	<keyword>recurrent gallbladder cancer</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>small intestine adenocarcinoma</keyword>
	<keyword>recurrent small intestine cancer</keyword>
	<keyword>recurrent islet cell carcinoma</keyword>
	<keyword>recurrent pheochromocytoma</keyword>
	<keyword>metastatic pheochromocytoma</keyword>
	<keyword>pulmonary carcinoid tumor</keyword>
	<keyword>thyroid gland medullary carcinoma</keyword>
	<keyword>metastatic gastrointestinal carcinoid tumor</keyword>
	<keyword>recurrent gastrointestinal carcinoid tumor</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>insulinoma</keyword>
	<keyword>WDHA syndrome</keyword>
	<keyword>glucagonoma</keyword>
	<keyword>pancreatic polypeptide tumor</keyword>
	<keyword>somatostatinoma</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
	<keyword>intraocular melanoma</keyword>
	<keyword>conjunctival melanoma</keyword>
	<keyword>iris melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
</DOC>